Study of the effectiveness of avonex in multiple sclerosis (1-year treatment)

Cover Page


Cite item

Abstract

In the paper, the results of 1-year treatment with avonex, a new immunomodulator from the group of interferons b, in 34 patients with relapsing remitting multiple sclerosis have been reported. In the treated patients it was shown significant decrease of the activity of the pathological process, which was evidenced by reduction of the severity of exacerbations and the relapse rate. The decrease of disability of patients with multiple sclerosis (by EDSS score) was revealed. In general, one can notice good tolerability of avonex.

 

About the authors

I. A. Zavalishin

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Author for correspondence.
Email: platonova@neurology.ru
Russian Federation

A. V. Peresedova

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
Russian Federation

N. I. Stoida

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
Russian Federation

L. Sh. Askarova

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
Russian Federation

M. N. Zakharova

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
Russian Federation

L. S. Adarcheva

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
Russian Federation

A. S. Niyazbekova

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
Russian Federation

O. V. Trifonova

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
Russian Federation

O. Yu. Rebrova

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
Russian Federation

D. D. Eliseeva

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
Russian Federation

References

  1. Biernacki K., Antel J.P., Blain M. et al. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol. 2005; 62: 563–568.
  2. Boutros T., Croze E., Yong V.W. Interferon-β is a potent promoter of nerve growth factor production by astrocytes. J. Neurochem. 1997; 69: 939–946.
  3. Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol. Sci. 2008; 29 (Suppl. 2): S253–255.
  4. Farrell R., Kapoor R., Leary S. et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of InterferonПbeta. Mult. Sclerоsis 2008; 14: 212–218.
  5. Gneiss C., Tripp P., Reichartseder F. et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult. Scler. 2006; 12: 731–737.
  6. Goodin D.S., Frohman E.M., Hurwitz B. et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 977–984.
  7. Jacobs L.D., Cookfair D.L., Rudick R.A. et al. Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann. Neurol. 1996; 39: 285–294.
  8. Rudick R.A., Goodkin D.E., Jacobs L.D. et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Neurology 1997; 49: 358–363.
  9. Simon J.H., Jacobs L.D., Campion M. et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann. Neurol. 1996; 43: 79–87.
  10. Sorensen P.S., Deisenhammer F., Duda P. et al. Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis. Europ. J. Neurol. 2005; 12: 817–827.
  11. Zidanov R., Locatelli L., Cookfair D. et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult. Sclerosis 2007; 13: 490–501.
  12. Zidanov R., Munschauer F.E., Ramanathan M. et al. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon beta-1a in patients with MS and CIS. Drugs Today (Barc.) 2008; 44: 601–613.

Copyright (c) 2009 Zavalishin I.A., Peresedova A.V., Stoida N.I., Askarova L.S., Zakharova M.N., Adarcheva L.S., Niyazbekova A.S., Trifonova O.V., Rebrova O.Y., Eliseeva D.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies